Temporal Variations in Patterns of Strain Diversity and Antibiotic Resistance in Thailand

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2021 Jul 2

PMID 34199301

Citations 3

Authors

Supapit Wongkuna

Tavan Janvilisri

Matthew Phanchana

Phurt Harnvoravongchai

Amornrat Aroonnual

Sathid Aimjongjun

Natamon Malaisri

Surang Chankhamhaengdecha

Affiliations

Soon will be listed here.

Abstract

has been recognized as a life-threatening pathogen that causes enteric diseases, including antibiotic-associated diarrhea and pseudomembranous colitis. The severity of infection (CDI) correlates with toxin production and antibiotic resistance of In Thailand, the data addressing ribotypes, toxigenic, and antimicrobial susceptibility profiles of this pathogen are scarce and some of these data sets are limited. In this study, two groups of isolates in Thailand, including 50 isolates collected from 2006 to 2009 (THA group) and 26 isolates collected from 2010 to 2012 (THB group), were compared for toxin genes and ribotyping profiles. The production of toxins A and B were determined on the basis of toxin gene profiles. In addition, minimum inhibitory concentration of eight antibiotics were examined for all 76 isolates. The isolates of the THA group were categorized into 27 (54%) and 23 (46%), while the THB isolates were classified into five toxigenic profiles, including six (23%), two (8%), five (19%), seven (27%), and six (23%). By visually comparing them to the references, only five ribotypes were identified among THA isolates, while 15 ribotypes were identified within THB isolates. Ribotype 017 was the most common in both groups. Interestingly, 18 unknown ribotyping patterns were identified. Among eight -positive isolates, three isolates showed significantly greater levels of toxin A than the reference strain. The levels of toxin B in 3 of 47 -positive isolates were significantly higher than that of the reference strain. Based on the antimicrobial susceptibility test, metronidazole showed potent efficiency against most isolates in both groups. However, high MIC values of cefoxitin (MICs 256 μg/mL) and chloramphenicol (MICs ≥ 64 μg/mL) were observed with most of the isolates. The other five antibiotics exhibited diverse MIC values among two groups of isolates. This work provides evidence of temporal changes in both strains and patterns of antimicrobial resistance in Thailand.

Citing Articles

The inhibitory effects of live and UV-killed Akkermansia muciniphila and its derivatives on cytotoxicity and inflammatory response induced by Clostridioides difficile RT001 in vitro.

Nasiri G, Azimirad M, Goudarzi H, Amirkamali S, Yadegar A, Ghalavand Z Int Microbiol. 2023; 27(2):393-409.

PMID: 37479958 DOI: 10.1007/s10123-023-00398-2.

Genomic Epidemiology and Antimicrobial Resistance Profiles of from Multi-Hospitals in a City in Eastern China.

Shu C, Zhou J, Yu H, Fu W, Shen J, Liang L Infect Drug Resist. 2023; 16:3379-3388.

PMID: 37274358 PMC: 10239244. DOI: 10.2147/IDR.S407497.

Introduction to the Special Issue on .

Granata G, Donno D Antibiotics (Basel). 2021; 10(10).

PMID: 34680813 PMC: 8532899. DOI: 10.3390/antibiotics10101233.

References

Indra A, Schmid D, Huhulescu S, Hell M, Gattringer R, Hasenberger P . Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. J Med Microbiol. 2008; 57(Pt 6):702-708. DOI: 10.1099/jmm.0.47476-0. View

Senoh M, Kato H, Fukuda T, Niikawa A, Hori Y, Hagiya H . Predominance of PCR-ribotypes, 018 (smz) and 369 (trf) of Clostridium difficile in Japan: a potential relationship with other global circulating strains?. J Med Microbiol. 2015; 64(10):1226-1236. DOI: 10.1099/jmm.0.000149. View

Kim Y, Park K, Park D, Park J, Bang B, Lee S . Guideline for the Antibiotic Use in Acute Gastroenteritis. Infect Chemother. 2019; 51(2):217-243. PMC: 6609748. DOI: 10.3947/ic.2019.51.2.217. View

Drudy D, Fanning S, Kyne L . Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis. 2006; 11(1):5-10. DOI: 10.1016/j.ijid.2006.04.003. View

Obuch-Woszczatynski P, Dubiel G, Harmanus C, Kuijper E, Duda U, Wultanska D . Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland. Eur J Clin Microbiol Infect Dis. 2013; 32(8):1027-30. PMC: 3706722. DOI: 10.1007/s10096-013-1845-5. View

Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J . Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366(9491):1079-84. DOI: 10.1016/S0140-6736(05)67420-X. View

He M, Miyajima F, Roberts P, Ellison L, Pickard D, Martin M . Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2012; 45(1):109-13. PMC: 3605770. DOI: 10.1038/ng.2478. View

Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr F, Zali M . Antimicrobial susceptibility of clostridium difficile clinical isolates in iran. Iran Red Crescent Med J. 2014; 15(8):704-11. PMC: 3918196. DOI: 10.5812/ircmj.5189. View

Ling Z, Liu X, Jia X, Cheng Y, Luo Y, Yuan L . Impacts of infection with different toxigenic Clostridium difficile strains on faecal microbiota in children. Sci Rep. 2014; 4:7485. PMC: 4265774. DOI: 10.1038/srep07485. View

10.

Bagdasarian N, Rao K, Malani P . Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015; 313(4):398-408. PMC: 6561347. DOI: 10.1001/jama.2014.17103. View

11.

Buchler A, Rampini S, Stelling S, Ledergerber B, Peter S, Schweiger A . Antibiotic susceptibility of Clostridium difficile is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. BMC Infect Dis. 2014; 14:607. PMC: 4247760. DOI: 10.1186/s12879-014-0607-z. View

12.

Zhu D, Sorg J, Sun X . Biology: Sporulation, Germination, and Corresponding Therapies for Infection. Front Cell Infect Microbiol. 2018; 8:29. PMC: 5809512. DOI: 10.3389/fcimb.2018.00029. View

13.

Ofosu A . Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016; 29(2):147-54. PMC: 4805733. DOI: 10.20524/aog.2016.0006. View

14.

Eckert C, Emirian A, Le Monnier A, Cathala L, De Montclos H, Goret J . Prevalence and pathogenicity of binary toxin-positive Clostridium difficile strains that do not produce toxins A and B. New Microbes New Infect. 2015; 3:12-7. PMC: 4337936. DOI: 10.1016/j.nmni.2014.10.003. View

15.

OConnor J, Galang M, Sambol S, Hecht D, Vedantam G, Gerding D . Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008; 52(8):2813-7. PMC: 2493101. DOI: 10.1128/AAC.00342-08. View

16.

Kato H, Kato N, Katow S, MAEGAWA T, Nakamura S, Lyerly D . Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin B-positive Clostridium difficile strains. FEMS Microbiol Lett. 1999; 175(2):197-203. DOI: 10.1111/j.1574-6968.1999.tb13620.x. View

17.

Putsathit P, Maneerattanaporn M, Piewngam P, Knight D, Kiratisin P, Riley T . Antimicrobial susceptibility of isolated in Thailand. Antimicrob Resist Infect Control. 2017; 6:58. PMC: 5465545. DOI: 10.1186/s13756-017-0214-z. View

18.

Peng Z, Addisu A, Alrabaa S, Sun X . Antibiotic Resistance and Toxin Production of Isolates from the Hospitalized Patients in a Large Hospital in Florida. Front Microbiol. 2018; 8:2584. PMC: 5744170. DOI: 10.3389/fmicb.2017.02584. View

19.

Xu X, Godoy-Ruiz R, Adipietro K, Peralta C, Ben-Hail D, Varney K . Structure of the cell-binding component of the binary toxin reveals a di-heptamer macromolecular assembly. Proc Natl Acad Sci U S A. 2020; 117(2):1049-1058. PMC: 6969506. DOI: 10.1073/pnas.1919490117. View

20.

Borren N, Ghadermarzi S, Hutfless S, Ananthakrishnan A . The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS One. 2017; 12(5):e0176797. PMC: 5413003. DOI: 10.1371/journal.pone.0176797. View